SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2
http://www.w3.org/2000/01/rdf-schema#comment
"the mechanisms responsible for the angiogenic imbalance and the response to anti-VEGF therapy differ between Eng and Alk1 heterozygous mice and raise the need for systemic monitoring of anti-angiogenic therapy effects in HHT patients."
xsd:string
http://purl.uniprot.org/uniprot/#_4E9090B9632F0771ADAD4A9261A64D7216DACA3FA80B79BCAEF5FCCA620E7E74FD35C54FE2BEB36BA9636C5D39EB249D
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2
http://purl.uniprot.org/uniprot/Q61288
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2
http://purl.uniprot.org/uniprot/#_Q61288-mappedCitation-24061911
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D223D6E96B9A4CB9533E00C6EAC9B3C5C3D7302030D34DF01DC773EBF6498F6FC0B2D969FB34AFEEFFF66C0BBFEAC6F2